Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
SanBio Co ( (JP:4592) ) has shared an announcement.
SanBio Co., Ltd. announced the completion of a partial change application for the marketing approval of AKUUGO Suspension for Intracranial Implantation, a product designed to aid nerve regeneration in the brain. This step is crucial for the product’s eligibility for shipment, expected to commence in the second quarter of the fiscal year ending January 31, 2026. The announcement indicates minimal impact on the current fiscal year’s financial performance, but it underscores SanBio’s continued commitment to addressing unmet medical needs in regenerative medicine.
The most recent analyst rating on (JP:4592) stock is a Hold with a Yen1400.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd., founded in California in 2001 and headquartered in Tokyo, Japan, is a leader in regenerative medicine. The company focuses on researching, developing, manufacturing, and selling regenerative cell medicines, particularly for central nervous system disorders. Their flagship product, AKUUGO, is aimed at improving chronic motor paralysis associated with traumatic brain injury.
Average Trading Volume: 5,595,881
Technical Sentiment Signal: Buy
Current Market Cap: Yen266.5B
Learn more about 4592 stock on TipRanks’ Stock Analysis page.